Edited by Peter Hillerberg2 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
US core CPI hit 339.3 in September, the highest reading since the series began in 1997, per ORTEX Alt Data. The annual rate reached 3.7%, the strongest September print in two years. That keeps rate expectations elevated and is weighing on financial sector targets. Analysts trimmed consensus prices on SCHW, SPGI, MCO, ARES, and APO this week. KeyBanc also cut WDAY to Sector Perform, while Wells Fargo downgraded to Equal-Weight. The mixed US equity open reflects this caution. Dow and S&P 500 futures edged higher, but the Nasdaq slipped as Treasury Secretary Bessent stepped up economic pressure on Iran.
General Motors reports Tuesday and Tesla follows Wednesday. German car registration data leads GM revenue by 15 days and is running 133% above the same quarter last year, per ORTEX Alt Data. The same dataset leads Tesla revenue by 43 days and is up 269% year-on-year. Neither figure is a forecast of the reported number, but the divergence between the two is the sharpest on record in ORTEX's backtest. Short sellers are watching Tesla closely. Its SI % of free float sits elevated, while options flow for the week has been skewed heavily toward the coming print.
Nestlé published its quarterly update today. Arm Holdings is in focus after news of a dispute with QUALCOMM. On the index radar, Fabrinet's deletion probability from MSCI World jumped from 8% to 49% overnight, per ORTEX Index Rebalance Radar. The ranking cut-off is Sunday, 19 October. Trackers face a potential $826M of forced selling, equal to 2.4 days of normal volume. Xero also carries a 73% deletion probability from MSCI World, with $393M of forced selling in play. The Copart tender for ACVA carries a 93% completion probability. An index deletion announcement is expected today, triggering an estimated $276M of combined selling across Russell 2000, Russell 3000, and MSCI World Small.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
